All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial ...

It was a busy week in the biotech sector with important regulatory and pipeline updates. Among these, Sarepta Therapeutics ...

Last July, the agency placed a hold on the trial due to a chromatographic signal detected in a human ADME study of the ...

Conduit Pharmaceuticals (CDT) provides an R&D update on the development progress of pipeline assets AZD1656, AZD5658, and AZD5904. The ...

The company plans to resume its CATT1 Phase 3 trial for type 1 diabetes after submitting a protocol amendment.

Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes. CATT1 Phase 3 trial expected to ...

Tv Therapeutics' Phase 3 trial for cadisegliatin in type 1 diabetes resumes after FDA lifts hold, with a revised six-month ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

On the path of innovative R&D, by practicing the model of joint innovation and working closely with enterprises in the ...

Shares of vTv Therapeutics rose after the Food and Drug Administration lifted a clinical hold on its diabetes treatment program. The stock gained 40% to $20.78 Monday morning. Shares have climbed ...